Cardiotonic agents Flashcards
Cardiac Glycosides
Digoxin (Lanoxin)
Actions of digoxin
Increases intracellular calcium, allows more calcium to enter the myocardial cell during depolarization; positive inotropic effect, increased renal perfusion with a diuretic effect and decrease in renin release, and slowed conduction through the AV node
Indications for digoxin
Treatment of HF, atrial fibrillation
C & C for digoxin
Contra- allergy, Vtach or Vfib, Heart block or sick sinus syndrome, Idiopathic hypertropic subaortic stenosis, Acute MI, renal insufficiency and electrolyte abnormalities.
Caution- pregnancy and lactation, pediatric and geriatric patients.
Pharmo for digoxin
Route- oral, IV
Onset- 30-120 min, 5-30 min
Peak- 2-6h, 1-5 h
Dx- 6-8 d, 4-5 d
T 1/2- 5-30min
Rapidly absorbed and widely distributed throughout the body
Primarily excreted unchanged in the urine
Adverse effects for digoxin
Headache, weakness, drowsiness, and vision changes
GI upset and anorexia
Arrhythmia development
D2D for digoxin
Verapamil, amiodarone, quinidine, quinine, erythromycin, tetracycline, or cyclosporine.
Potassium losing diuretics
Cholestyramine, charcoal, colestipol, bleomycin, cyclophosphamide, or methotrexate
Special info for digoxin
Digoxin (lanoxin) can be given in a loading dose but you need to 0.1-0.25 mg/mL IV dosed is a normal dose. IF you question an order you need to look it up and then call the MD again.
HR less than 60 you need to hold this.
Phosphodiesterase inhibitors
Inamrinone (Inocor): Approved only for use in patients with HF that has not responded to digoxin, diuretics, or vasodilators
Milrinone (Primacor): Short-term management of HF in patients who are receiving digoxin and diuretics
Actions for Inamrinone (Inocor)
Blocks the enzyme phosphodiesterase, leads to an increase in myocardial cell cyclic adenosine monophosphate (cAMP), which increases calcium levels in the cell, causing a stronger contraction and prolonged response to sympathetic stimulation; directly relaxes vascular smooth muscle
Indications for Inamrinone
Short-term treatment of HF in patients unresponsive to digitalis, diuretics, or vasodilators
Pharmo for Inamrinone
Route- IV Onset- Immediate Peak- 10min Dx- 2hr T 1/2- 3.6 to 5.8 hrs Widely distributed after injection Metabolized in the liver and excreted in the urine
C & C for Inamrinone
Contra- allergy, sever aortic or pulmonic disease, MI, fluid volume deficit, and ventricular arrhythmias
Caution- pregnancy or lactation, elderly.
Adverse effects for Inamrinone
Arrhythmias, Hypotension, Nausea, Vomiting
Thrombocytopenia, Pericarditis
Pleuritis,Fever, Chest Pain
Burning at Injection Site
You have lots of problems with phosphodiesterase inhibitors thus it is not the primary drug of choice and you need to do a CBC to monitor for thrombocytopenia.
D2 D interaction for Inamrione
Furosemide